# Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

> **NCT01284946** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 45 (estimated)

## Conditions studied

- Porphyria Cutanea Tarda

## Interventions

- **DRUG:** Exjade

## Key facts

- **NCT ID:** NCT01284946
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2011-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284946, "Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01284946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*